Clinical Trial Update: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study evaluating the WT1 peptide vaccine in patients with multiple myeloma after autologous stem cell transplantation have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• WT1 Vaccine (WT1 peptide vaccine)

Snippet

Sponsor: Sellas Life Sciences Group | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-09-19